← back to search

Hongyu Li

Guiyang Medical University · CN
Area of research
Organic Chemistry · Molecular Biology
Research interest
Research interests include Multicomponent Synthesis of Heterocycles, Catalytic C–H Functionalization Methods, Protein Degradation and Inhibitors, and Synthesis and biological activity.
h-index
42
citations
6,877
works
248
NIH funding
primary concept
email

Recent publications

Lactam enables remote boronate rearrangements to C═N bonds.
2026cited by 0position: contributordoi
Design, Synthesis, and Biological Evaluation of Thieno[3,2-<i>d</i>]pyrimidine Derivatives as the First Bifunctional PI3Kδ Isoform Selective/Bromodomain and Extra-Terminal Inhibitors.
2025cited by 9position: contributordoi
Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
European Journal of Medicinal Chemistry 2025cited by 7position: contributordoi
Revisiting Aurora Kinase B: A promising therapeutic target for cancer therapy.
2024cited by 19position: contributordoi
An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L
European Journal of Medicinal Chemistry 2024cited by 8position: contributordoi
IMPA1-derived inositol maintains stemness in castration-resistant prostate cancer via IMPDH2 activation.
2024cited by 5position: contributordoi
Overcoming Secondary Mutations of Type II Kinase Inhibitors.
2024cited by 4position: contributordoi
Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective <i>via</i> Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss.
2024cited by 2position: contributordoi
A novel isocyanide/Ag<sub>2</sub>CO<sub>3</sub>-promoted addition of heteroatoms to alkynes under mild conditions
Organic Chemistry Frontiers 2023cited by 3position: contributordoi
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose.
2022cited by 10position: contributordoi
Dieckmann Condensation of Ugi <i>N</i>-Acylamino Amide Product: Facile Access to Functionalized 2,2-Disubstituted Indolin-3-ones.
2022cited by 9position: contributordoi
Feasible Column Chromatography-Free, Multi-Gram Scale Synthetic Process of VH032 Amine, Which Could Enable Rapid PROTAC Library Construction.
2022cited by 8position: contributordoi
Discovery of fused benzimidazole-imidazole autophagic flux inhibitors for treatment of triple-negative breast cancer.
2022cited by 7position: contributordoi
Zn(OTf)<sub>2</sub>-Promoted Isocyanide-Based Three-Component Reaction: Direct Access to 2-Oxazolines and β-Amino Amides.
2022cited by 2position: contributordoi
Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
2021cited by 22position: contributordoi
Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor
European Journal of Medicinal Chemistry 2021cited by 21position: contributordoi
Solvent‐Dependent Chemoselective and Stereoselective Approach to Synthesis of Spiro‐γ‐Lactams with Potent Anticancer Activity
Advanced Synthesis &amp; Catalysis 2021cited by 9position: contributordoi
Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors
European Journal of Medicinal Chemistry 2021cited by 4position: lastdoi
Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors.
2021cited by 2position: contributordoi
Dynamics of mcr-1 prevalence and mcr-1-positive Escherichia coli after the cessation of colistin use as a feed additive for animals in China: a prospective cross-sectional and whole genome sequencing-based molecular epidemiological study
The Lancet Microbe 2020cited by 134position: middledoi
Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology.
2020cited by 22position: contributordoi
The Exploration of Chirality for Improved Druggability within the Human Kinome.
2020cited by 19position: contributordoi
One-pot construction of functionalized aziridines and maleimides via a novel pseudo-Knoevenagel cascade reaction.
2020cited by 6position: contributordoi
Microwave-Assisted Copper Catalysis of α-Difluorinated <i>gem</i>-Diol toward Difluoroalkyl Radical for Hydrodifluoroalkylation of <i>para</i>-Quinone Methides.
2020cited by 5position: contributordoi
Spatiotemporal Dynamics of Intra-tumoral Dependence on NEK2-EZH2 Signaling in Glioblastoma Cancer Progression
bioRxiv (Cold Spring Harbor Laboratory) 2020cited by 2position: middledoi
Transition State Analogues Enhanced by Fragment-Based Structural Analysis: Bacterial Methylthioadenosine Nucleosidases.
2020cited by 2position: contributordoi
Strategy Used to Control the Mechanism of Homogeneous Alkyne/Olefin Hydrogenation: AIMD Simulations and DFT Calculations.
2020cited by 2position: contributordoi
Correction to Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.
2020cited by 1position: contributordoi
Lactate Is a Natural Suppressor of RLR Signaling by Targeting MAVS
Cell 2019cited by 578position: middledoi
Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.
2019cited by 66position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 28 papers (2019–2026)Zhigang Xu · American Chemical Society9 papers (2019–2026)Wei Yan · The University of Texas Health Science Center at San Antonio9 papers (2019–2026)Brendan Frett · University of Arizona9 papers (2013–2021) · 7 papers (2019–2026)Dianyong Tang · Chongqing University of Arts and Sciences6 papers (2019–2025)Zhongzhu Chen · Southwest University6 papers (2019–2026)Yuanxiang Wang · Shihezi University4 papers (2013–2015)Naga Rajiv Lakkaniga · Elsevier, Inc.3 papers (2020–2024)Francesca Carlomagno · American Chemical Society3 papers (2020–2022)Xiuqi Wang · China Pharmaceutical University3 papers (2022–2024)Brendan Frett · University of Arkansas for Medical Sciences3 papers (2020–2022)Zhuo Zhang · Shanghai Jiao Tong University2 papers (2017–2020) · 2 papers (2017–2020)Yong Xia · Guangzhou Medical University2 papers (2017–2020) · 2 papers (2023–2026)Cheng-He Zhou · American Chemical Society2 papers (2019–2022)Jaideep B. Bharate · University of Arkansas for Medical Sciences2 papers (2021–2022)Lingtian Zhang · University of Arkansas for Medical Sciences2 papers (2021–2021)Yohei Doi · University of Pittsburgh2 papers (2017–2020)